Comparative Pharmacology
Head-to-head clinical analysis: LODINE XL versus PROFENAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LODINE XL versus PROFENAL.
LODINE XL vs PROFENAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis leading to anti-inflammatory, analgesic, and antipyretic effects.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis, thereby exerting analgesic, anti-inflammatory, and antipyretic effects.
400 mg or 600 mg orally once daily.
600 mg orally every 6 to 8 hours as needed for pain; or 1000 mg orally every 6 to 8 hours for antipyresis; maximum single dose 1000 mg, maximum daily dose 4000 mg.
None Documented
None Documented
Terminal elimination half-life is approximately 6-7 hours. Steady-state is achieved within 2 days.
6-8 hours (terminal); requires dosing every 6-8 hours to maintain therapeutic levels
Renal excretion of metabolites accounts for approximately 70% of a dose; fecal excretion accounts for about 20%.
Primarily renal (approximately 70% as metabolites, <5% unchanged), biliary/fecal (30%)
Category C
Category C
NSAID
NSAID